| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6166134 | Urology | 2014 | 7 Pages |
Abstract
Alterations in mTOR pathway correlate with established adverse pathologic features and independently predict inferior oncologic outcomes. Incorporation of mTOR-based marker profiles may allow for enhanced patient counseling, risk stratification, and individualized treatment regimens.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Aditya Bagrodia, Laura-Maria Krabbe, Bishoy A. Gayed, Payal Kapur, Ira Bernstein, Xian-Jin Xie, Christopher G. Wood, Jose A. Karam, Alon Z. Weizer, Jay D. Raman, Mesut Remzi, Nathalie Rioux-Leclerq, Andrea Haitel, Marco Roscigno, Christian Bolenz,